Abstract
Although the clinical development of Io has ushered in a new era of anti-tumor therapy, mCRC is considered to be an immune-excluded tumor, being one of the tumor types in which Io has proven to be less effective. Microsatellite instability (MSI) status is currently the only biomarker for Io response in mCRC, being present in only 5% of mCRC pts. Most pts with microsatellite stability (MSS) mCRC do not respond to Io or do not have durable clinical responses, therefore it is necessary to obtain reliable predictors of response to Io.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
